Outcome Measures | Values |
---|---|
ACR20 | 69/169 (40.8) |
Polyarthritis | 56/121 (46.3) |
Oligoarthritis | 13/48 (27.1) |
ACR50 | 32/170 (18.8) |
Polyarthritis | 23/121 (19.0) |
Oligoarthritis | 9/49 (18.4) |
ACR70 | 15/174 (8.6) |
Polyarthritis | 13/125 (10.4) |
Oligoarthritis | 2/49 (4.1) |
MDA | 39/174 (22.4) |
Polyarthritis | 21/125 (16.8) |
Oligoarthritis | 18/49 (36.7) |
Change in PASDAS at 12 weeks | −1.11 (−2.14 to −0.40) |
Polyarthritis | −1.17 (−2.21 to −0.35) |
Oligoarthritis | −1.03 (−1.65 to −0.64) |
PASDAS low disease activity ≤ 3.2 | 63 (32.5) |
Polyarthritis | 35 (25.0) |
Oligoarthritis | 28 (51.9) |
PASDAS good response | 35 (18.0) |
Polyarthritis | 24 (17.1) |
Oligoarthritis | 11 (20.4) |
PASDAS moderate response | 76 (39.2) |
Polyarthritis | 53 (37.9) |
Oligoarthritis | 23 (42.6) |
Change in TJC | −2 (−6.25 to 1) |
Change in SJC | −3 (−6, −1) |
PASI75 | 43/158 (27.2) |
Change in mNAPSI | −2 (−8 to 0) |
Enthesitis all resolved | 38/148 (25.7) |
Change in Leeds Enthesitis Index | 0 (−1 to 0) |
Change in IMPACT enthesitis score | 0 (−1 to 0) |
Change in MASES | 0 (−2 to 1) |
Dactylitis all resolved | 37/59 (62.7) |
Change in Leeds dactylitis instrument basic score | −59.7 (−157.4 to −26.4) |
Change in PsAQoL | −1 (−4 to 1) |
Change in HAQ | −0.1875 (−0.5 to 0.0) |
Reduction in HAQ ≥ MCID = 0.35 | 69/188 (36.7) |
Change in patient’s global disease activity VAS | −13.5 (−34 to 1.75) |
Change in patient pain VAS | −13 (−32.25 to 0) |
Change in patient fatigue VAS | −2 (−20 to 8) |
MTX: methotrexate; IQR: interquartile range; ACR: American College of Rheumatology; MDA: minimal disease activity; PASDAS: Psoriatic Arthritis Disease Activity Score; TJC: tender joint count; SJC: swollen joint count; PASI: Psoriasis Area and Severity Index; mNAPSI: modified Nail Psoriasis Severity Index; IMPACT: Infliximab Multinational Psoriatic Arthritis Controlled Trial; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; PsAQoL: psoriatic arthritis quality of life questionnaire; HAQ: Health Assessment Questionnaire; MCID: minimum clinically important difference; VAS: visual analog scale.